Public Market Listing
Live quotes, historical charts, and market capitalization for CSPC Pharmaceutical Group are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(11 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Serotonin/norepinephrine transporterSmall molecule | Major Depressive Disorder | |
| Phase 3 | HER2 (biparatopic — extracellular domains II and IV)Antibody–drug conjugate | Breast CancerColorectal Cancer HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer | |
Efmedaglutide alfa(Shanmeining) | Phase 3 | GLP-1 receptorProtein / enzyme therapeutic | ObesityType 2 Diabetes |
| Phase 3 | Angiotensin II type 1 receptor / L-type calcium channel (dual)Small molecule | Hypertension | |
Prusogliptin(Shanzeping) | Phase 3 | DPP-4Small molecule | Type 2 Diabetes |
| Phase 3 | FLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Small molecule | Acute Myeloid Leukemia | |
| Phase 3 | PCSK9RNA / oligonucleotide | Atherosclerotic Cardiovascular Disease | |
| Phase 3 | JAK/SYKSmall molecule | Psoriasis | |
| Phase 2 | LPA gene / apolipoprotein(a) mRNARNA / oligonucleotide | Atherosclerotic Cardiovascular Disease | |
| Phase 2 | ANGPTL3RNA / oligonucleotide | Atherosclerotic Cardiovascular DiseaseCardiovascular Disease / Dyslipidemia Hypertriglyceridemia | |
| Preclinical / Unstaged | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia |
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (6)
April 2027 (2)
May 2027 (1)
September 2027 (1)
December 2027 (2)
2028 (2)
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $3.6B | $809M | $1.4B | — | report ↗ |